首页> 外文期刊>Clinical Hypertension >Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial
【24h】

Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial

机译:钙通道阻滞剂和利尿剂联合血管紧张素II受体阻滞剂对高血压患者24小时中心血压和血管血流动力学参数的影响比较:多中心,双盲,主动控制的4期随机试验研究设计

获取原文
           

摘要

Background Hypertension is a risk factor for coronary heart disease and stroke, and is one of the leading causes of death. Although over a billion people are affected worldwide, only half of them receive adequate treatment. Current guidelines on antihypertensive treatment recommend combination therapy for patients not responding to monotherapy, but as the number of pills increase, patient compliance tends to decrease. As a result, fixed-dose combination drugs with different antihypertensive agents have been developed and widely used in recent years. CCBs have been shown to be better at reducing central blood pressure and arterial stiffness than diuretics. Recent studies have reported that central blood pressure and arterial stiffness are associated with cardiovascular outcomes. This trial aims to compare the efficacy of combination of calcium channel blocker (CCB) or thiazide diuretic with an angiotensin receptor blocker (ARB). Methods This is a multicenter, double-blinded, active-controlled, phase 4, randomized trial, comparing the antihypertensive effects of losartan/amlodipine and losartan/hydrochlorothiazide in patients unresponsive to treatment with losartan. The primary endpoint is changes in mean sitting systolic blood pressure (msSBP) after 4?weeks of treatment. Secondary endpoints are changes in msSBP, mean 24-h ambulatory mobile blood pressure, mean 24-h ambulatory mobile central SBP, mean 24-h ambulatory carotid-femoral pulse wave velocity, ambulatory augmentation index, and microalbuminuria/proteinuria after 20?weeks of treatment. The sample size will be 119 patients for each group in order to confer enough power to test for non-inferiority regarding the primary outcome. Conclusion The investigators aim to prove that combination of a CCB with ARB shows non-inferiority in lowering blood pressure compared with a combination of thiazide diuretic and ARB. We also hope to distinguish the subset of patients that are more responsive to certain types of combination drugs. The results of this study should aid physicians in selecting appropriate combination regimens to treat hypertension in certain populations. Trial registration ClinicalTrials.gov NCT02294539. Registered 12 November 2014.
机译:背景技术高血压是冠心病和中风的危险因素,并且是主要的死亡原因之一。尽管全世界有超过十亿人受到影响,但其中只有一半得到了适当的治疗。当前的抗高血压治疗指南建议对单药治疗无效的患者进行联合治疗,但是随着药丸数量的增加,患者的依从性往往会下降。结果,近年来开发了具有不同抗高血压药的固定剂量组合药物并被广泛使用。与利尿剂相比,CCBs在降低中心血压和动脉僵硬方面表现出更好的效果。最近的研究报道,中心血压和动脉僵硬与心血管疾病的结果有关。该试验旨在比较钙通道阻滞剂(CCB)或噻嗪类利尿剂与血管紧张素受体阻滞剂(ARB)的疗效。方法这是一项多中心,双盲,主动控制,4期随机试验,比较了氯沙坦/氨氯地平和氯沙坦/氢氯噻嗪对氯沙坦治疗无效的患者的降压作用。主要终点是治疗4周后平均坐姿收缩压(msSBP)的变化。次要终点是20s周后,msSBP,平均24小时动态门诊血压,平均24小时动态门诊中枢SBP,平均24小时动态颈动脉-股动脉脉搏波速度,动态门诊增强指数以及微量白蛋白尿/蛋白尿的变化。治疗。每个组的样本量为119名患者,以赋予足够的能力来检验有关主要结局的非劣效性。结论研究者旨在证明CCB与ARB的组合与噻嗪类利尿剂和ARB的组合在降低血压方面没有劣势。我们还希望区分对某些类型的组合药物反应更强的患者子集。这项研究的结果应有助于医生选择合适的联合疗法来治疗某些人群的高血压。试用注册ClinicalTrials.gov NCT02294539。 2014年11月12日注册。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号